benchmark holdings plc said thursday that its thirdquarter pretax loss significantly widened on a major increase in net finance costs though revenue rose the aquaculture biotechnology company posted a pretax loss of 112 million pounds 132 million for the three months ended june 30 compared with a loss of gbp27 million a year earlier it attributed the loss to foreignexchange losses and a reduction in fair value of financial instruments revenue stood at gbp363 million up from gbp283 million in the same quarter last year due to a strong performance from its genetics and health units the company said it was performing in line with its fullyear expectations with a strong outlook for its genetics and advanced nutrition sales for the remainder of fiscal 2022 benchmark said fiscal 2023 is expected to be a transitional year for its health business as it assumes transfer of some of its cleantreat product capacity to a new business model it said this will result in limited growth in health adjusted earnings in fiscal 2023 but lead to a less capital intensive solution after we are excited about the development of a new configuration and business model for cleantreat which although reducing our growth rate for next year increases our confidence in the solution and enhances benchmarks long term prospects chief executive trond williksen said